Importantly, in addition to LPMs, different peritoneal macrophage subpopulations with protumor potential have been recently identified, including Lyve‐1+ CD163+ omental macrophages, and Lyve‐1high MHCIIlow mesenteric and peritoneal wall macrophages that, consequently, have to be taken into account in the design of experiments aiming at exploring the tumor promoting function of peritoneal macrophages, and in the development of immunotherapeutical antitumor strategies. The gene discussed is LYVE1; the disease is neoplasm.